Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2025-01-03 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2025-01-03 English
PRIMARY DOCUMENT
Director's Dealing
2025-01-03 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically discusses an increase in the maximum aggregate offering price under an At The Market Offering Agreement, which relates to financing activities. The document length is 3600 characters, which is relatively short and focused on a capital raising update. There is no detailed financial data or comprehensive report content, so it is not an Annual Report, Interim Report, or Earnings Release. The primary subject is an update on the company's capital raising activity, fitting the Capital/Financing Update category.
2024-12-23 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement on Form S-3. It details an offering of common stock by MAIA Biotechnology, Inc., including terms of the offering, risk factors, use of proceeds, dilution, and plan of distribution. The document is a legal and regulatory filing related to capital raising activities, specifically an update and amendment to prior prospectuses for an at-the-market offering. It is not a financial report, earnings release, management discussion, or any other type of report but rather a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not merely an announcement or a brief notice, supporting high confidence in this classification.
2024-12-23 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a press release about the FDA designating a drug for a rare pediatric disease, which is an event announcement. There are no financial statements or detailed financial data included. The document is not an annual or quarterly report, audit report, or earnings release. It is not a proxy, voting result, or management change announcement. The document is a regulatory filing reporting a material event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is over 6000 characters, so it is not a brief report publication announcement. Confidence is high due to the clear identification as a Form 8-K and the nature of the content.
2024-12-20 English
PRIMARY DOCUMENT
Director's Dealing
2024-12-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.